Baseline Total Metabolic Tumour Volume Is Highly Prognostic for Refractoriness to Immunochemotherapy in Dlbcl: An Analysis of the Phase 3 Goya Trial

Hematological Oncology - United Kingdom
doi 10.1002/hon.20_2629

Related search